

Postmenopausal Osteoporosis Treatment Market Forecasts to 2034 – Global Analysis By Treatment Type (Bisphosphonates, Hormone Replacement Therapy (HRT), Selective Estrogen Receptor Modulators (SERMs), Monoclonal Antibodies, Calcium and Vitamin D Supplements, Anabolic Agents and Other Treatment Types), By Route of Administrations (Oral, Parenteral, Transdermal and Nasal), By Drug Delivery System (Conventional Formulations and Long-Acting Formulations), Patient Demographics, Distribution Channel and By Geography

<https://marketpublishers.com/r/P35776E8C76AEN.html>

Date: May 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: P35776E8C76AEN

Abstracts

According to Statistics MRC, the Global Postmenopausal Osteoporosis Treatment Market is accounted for \$9.8 billion in 2026 and is expected to reach \$16.3 billion by 2034 growing at a CAGR of 6.6% during the forecast period. Postmenopausal osteoporosis treatment involves medications and lifestyle modifications to mitigate bone loss in women after menopause. Common treatments include bisphosphonates, hormone therapy, and monoclonal antibodies, which aim to strengthen bones and reduce fracture risk. These treatments help maintain bone density, alleviate symptoms and enhance overall bone health.

According to the World Health Organization's October 2021 report, the population of people of age 60 years and more is expected to increase from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. According to data published by the International Menopause Society (IMS), in 2021, more than 200 million women are estimated to

suffer from osteoporosis, and 1 in 3 women aged more than 50 is expected to experience osteoporosis fracture.

Market Dynamics:

Driver:

The increasing global aging population

With a rising number of individuals entering the postmenopausal phase, there is a subsequent increase in the prevalence of osteoporosis, a condition characterized by reduced bone density and increased fracture risk. This demographic shift creates a growing demand for effective treatment options to address the specific needs of postmenopausal women, fostering research and development initiatives.

Pharmaceutical companies are increasingly focusing on developing therapies tailored to this demographic, ranging from innovative drugs to targeted interventions, driving market growth as healthcare systems strive to meet the evolving needs of an aging population susceptible to osteoporosis-related complications.

Restraint:

High treatment costs

The financial burden associated with osteoporosis medications and therapies poses challenges to widespread accessibility and affordability, particularly for patients in regions with limited healthcare resources or inadequate insurance coverage. The cost of osteoporosis treatment often includes not only medication expenses but also diagnostic procedures, monitoring tests, and potential side-effect management, further exacerbating the economic burden on patients. As osteoporosis is a chronic condition requiring long-term management, the cumulative financial impact can dissuade individuals from seeking or continuing treatment.

Opportunity:

Growing awareness regarding the importance of bone health

As awareness grows regarding the risks and consequences of osteoporosis, there is a heightened demand for preventive and therapeutic interventions. Public education campaigns and healthcare initiatives play a pivotal role in encouraging individuals to

prioritize bone health, undergo timely screenings, and seek appropriate treatment. This heightened awareness not only fosters early diagnosis but also propels the adoption of osteoporosis treatments, creating a positive market environment where patients are more proactive in managing their bone health and preventing complications associated with postmenopausal osteoporosis.

Threat:

Adverse effects and safety issues

While various pharmaceutical interventions aim to address bone health in postmenopausal women, the potential for adverse reactions may lead to decreased patient compliance and treatment discontinuation. Common side effects such as gastrointestinal disturbances, musculoskeletal pain, and, in some cases, severe complications like atypical fractures or osteonecrosis of the jaw raise concerns among both patients and healthcare providers. These safety issues not only impact the quality of life for affected individuals but also undermine the market's credibility and trust.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the market. Lockdowns, disrupted healthcare services, and diverted resources to combat the virus have led to challenges in patient diagnosis and treatment accessibility. Delayed medical appointments and reduced patient visits have affected osteoporosis management. Additionally, supply chain disruptions have impacted drug availability. However, the pandemic has accelerated the adoption of telemedicine and digital health solutions, offering alternative avenues for patient care. The focus on overall healthcare resilience and the importance of preventive measures may influence post-pandemic strategies in managing postmenopausal osteoporosis.

The hormone replacement therapy is expected to be the largest during the forecast period

The hormone replacement therapy segment is expected to have a lucrative growth. In postmenopausal women, reduced estrogen levels result in increased bone resorption, elevating the risk of osteoporosis. HRT involves the administration of estrogen and sometimes progestin to mitigate these effects, promoting bone density maintenance and fracture prevention. Despite proven efficacy, HRT usage is carefully evaluated due to associated risks, such as cardiovascular concerns. Ongoing research focuses on

optimizing HRT protocols to maximize benefits while minimizing potential drawbacks in postmenopausal osteoporosis management.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is anticipated to witness the fastest CAGR growth during the forecast period. They ensure the availability of prescribed treatments, provide patient education, and facilitate seamless coordination between healthcare professionals and individuals undergoing postmenopausal osteoporosis treatment. Hospital pharmacies contribute to treatment adherence through their expertise in medication management, offering a centralized hub for patients to obtain necessary medications, including emerging and innovative therapies. This integral role underscores their significance in supporting effective healthcare delivery and promoting positive outcomes in the management of postmenopausal osteoporosis.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market driven by a substantial aging population and advanced healthcare infrastructure. The region benefits from a high prevalence of postmenopausal osteoporosis, necessitating a robust demand for effective treatments. Technological advancements, well-established pharmaceutical companies, and favorable reimbursement policies contribute to the market's growth. Moreover, ongoing research initiatives and clinical trials in the region focus on innovative therapies, positioning North America as a key hub for the development and commercialization of new and advanced treatments for postmenopausal osteoporosis.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, driven by a growing health-conscious population. The increasing aging population, particularly in countries like Japan and China, contributes to a higher prevalence of osteoporosis, driving the demand for effective treatments. Rising healthcare awareness, improving access to medical facilities, and government initiatives to address women's health issues further propel market expansion. Additionally, collaborations between pharmaceutical companies and healthcare organizations, coupled with advancements in treatment options, are fostering innovation and enhancing the overall landscape for postmenopausal osteoporosis treatment in the Asia Pacific region.

Key players in the market

Some of the key players in Postmenopausal Osteoporosis Treatment market include AbbVie Company (Allergan Pharmaceuticals International Ltd.), Sun Pharmaceutical Industries Ltd., Amgen Inc., BiologicsMD, Chugai Pharma China Co., Ltd. (Roche), Clonz Biotech, Proctor & Gamble Co., Eli Lilly and Company, Enteris BioPharma, Ligand Pharmaceuticals Incorporated., Pfizer Inc., Merck Sharp & Dohme Corp. (Merck & Co., Inc.), Mylan Inc. (Viatris), Oncobiologics, Inc. and Novartis International AG.

Key Developments:

In February 2023, Sandoz received Biologics License Application (BLA) from US Food and Drug Administration (FDA) for a prospective biosimilar of denosumab (Prolia and Xgeva; Amgen). The product is intended for addressing a wide range of conditions, such as osteoporosis in postmenopausal women and in men with an elevated fracture risk, alongside numerous other medical conditions.

In July 2022, Chugai Pharma China Co., Ltd., a subsidiary of Chugai Pharmaceutical Co., Ltd. launched Ediol (eldecalcitol) in China after receiving approval from the China National Medical Products Administration (NMPA) for the treatment of postmenopausal osteoporosis. Ediol is an active vitamin D3 derivative created by Chugai.

Treatment Types Covered:

Bisphosphonates

Hormone Replacement Therapy (HRT)

Selective Estrogen Receptor Modulators (SERMs)

Monoclonal Antibodies

Calcium and Vitamin D Supplements

Anabolic Agents

Other Treatment Types

Route of Administrations Covered:

Oral

Parenteral

Transdermal

Nasal

Drug Delivery Systems Covered:

Conventional Formulations

Long-Acting Formulations

Patient Demographics Covered:

Postmenopausal Women

Elderly Population

Distribution Channels Covered:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Emerging Markets
- 3.7 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS TREATMENT MARKET, BY TREATMENT TYPE

- 5.1 Introduction
- 5.2 Bisphosphonates
- 5.3 Hormone Replacement Therapy (HRT)
- 5.4 Selective Estrogen Receptor Modulators (SERMs)
- 5.5 Monoclonal Antibodies
- 5.6 Calcium and Vitamin D Supplements
- 5.7 Anabolic Agents
- 5.8 Other Treatment Types

6 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

- 6.1 Introduction
- 6.2 Oral
- 6.3 Parenteral
 - 6.3.1 Intravenous (IV)
 - 6.3.2 Intramuscular
 - 6.3.3 Subcutaneous
- 6.4 Transdermal
- 6.5 Nasal

7 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS TREATMENT MARKET, BY DRUG DELIVERY SYSTEM

- 7.1 Introduction
- 7.2 Conventional Formulations
- 7.3 Long-Acting Formulations

8 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS TREATMENT MARKET, BY PATIENT DEMOGRAPHICS

- 8.1 Introduction
- 8.2 Postmenopausal Women
- 8.3 Elderly Population

9 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

- 9.1 Introduction
- 9.2 Hospital Pharmacies
- 9.3 Retail Pharmacies
- 9.4 Online Pharmacies

10 GLOBAL POSTMENOPAUSAL OSTEOPOROSIS TREATMENT MARKET, BY GEOGRAPHY

- 10.1 Introduction
- 10.2 North America
 - 10.2.1 US
 - 10.2.2 Canada
 - 10.2.3 Mexico
- 10.3 Europe
 - 10.3.1 Germany
 - 10.3.2 UK
 - 10.3.3 Italy
 - 10.3.4 France
 - 10.3.5 Spain
 - 10.3.6 Rest of Europe
- 10.4 Asia Pacific
 - 10.4.1 Japan
 - 10.4.2 China
 - 10.4.3 India
 - 10.4.4 Australia
 - 10.4.5 New Zealand
 - 10.4.6 South Korea
 - 10.4.7 Rest of Asia Pacific
- 10.5 South America
 - 10.5.1 Argentina
 - 10.5.2 Brazil
 - 10.5.3 Chile
 - 10.5.4 Rest of South America
- 10.6 Middle East & Africa
 - 10.6.1 Saudi Arabia
 - 10.6.2 UAE
 - 10.6.3 Qatar
 - 10.6.4 South Africa
 - 10.6.5 Rest of Middle East & Africa

11 KEY DEVELOPMENTS

- 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 11.2 Acquisitions & Mergers
- 11.3 New Product Launch
- 11.4 Expansions
- 11.5 Other Key Strategies

12 COMPANY PROFILING

- 12.1 AbbVie Company (Allergan Pharmaceuticals International Ltd.)
- 12.2 Sun Pharmaceutical Industries Ltd.
- 12.3 Amgen Inc.
- 12.4 BiologicsMD
- 12.5 Chugai Pharma China Co., Ltd. (Roche)
- 12.6 Clonz Biotech
- 12.7 Proctor & Gamble Co.
- 12.8 Eli Lilly and Company
- 12.9 Enteris BioPharma
- 12.10 Ligand Pharmaceuticals Incorporated.
- 12.11 Pfizer Inc.
- 12.12 Merck Sharp & Dohme Corp. (Merck & Co., Inc.)
- 12.13 Mylan Inc. (Viatris)
- 12.14 Oncobiologics, Inc.
- 12.15 Novartis International AG

List Of Tables

LIST OF TABLES

Table 1 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Region (2023-2034) (\$MN)

Table 2 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Treatment Type (2023-2034) (\$MN)

Table 3 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Bisphosphonates (2023-2034) (\$MN)

Table 4 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Hormone Replacement Therapy (HRT) (2023-2034) (\$MN)

Table 5 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2023-2034) (\$MN)

Table 6 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Monoclonal Antibodies (2023-2034) (\$MN)

Table 7 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Calcium and Vitamin D Supplements (2023-2034) (\$MN)

Table 8 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Anabolic Agents (2023-2034) (\$MN)

Table 9 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Other Treatment Types (2023-2034) (\$MN)

Table 10 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Route of Administration (2023-2034) (\$MN)

Table 11 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Oral (2023-2034) (\$MN)

Table 12 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Parenteral (2023-2034) (\$MN)

Table 13 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Intravenous (IV) (2023-2034) (\$MN)

Table 14 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Intramuscular (2023-2034) (\$MN)

Table 15 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Subcutaneous (2023-2034) (\$MN)

Table 16 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Transdermal (2023-2034) (\$MN)

Table 17 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Nasal (2023-2034) (\$MN)

Table 18 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Drug

Delivery System (2023-2034) (\$MN)

Table 19 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Conventional Formulations (2023-2034) (\$MN)

Table 20 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Long-Acting Formulations (2023-2034) (\$MN)

Table 21 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Patient Demographics (2023-2034) (\$MN)

Table 22 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Postmenopausal Women (2023-2034) (\$MN)

Table 23 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Elderly Population (2023-2034) (\$MN)

Table 24 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Distribution Channel (2023-2034) (\$MN)

Table 25 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Hospital Pharmacies (2023-2034) (\$MN)

Table 26 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Retail Pharmacies (2023-2034) (\$MN)

Table 27 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Online Pharmacies (2023-2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Postmenopausal Osteoporosis Treatment Market Forecasts to 2034 – Global Analysis By Treatment Type (Bisphosphonates, Hormone Replacement Therapy (HRT), Selective Estrogen Receptor Modulators (SERMs), Monoclonal Antibodies, Calcium and Vitamin D Supplements, Anabolic Agents and Other Treatment Types), By Route of Administrations (Oral, Parenteral, Transdermal and Nasal), By Drug Delivery System (Conventional Formulations and Long-Acting Formulations), Patient Demographics, Distribution Channel and By Geography

Product link: <https://marketpublishers.com/r/P35776E8C76AEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P35776E8C76AEN.html>